Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Acotec Scientific Holdings Limited ( (HK:6669) ) has issued an announcement.
Acotec Scientific Holdings Limited reported significant financial growth for the year ended December 31, 2024, with a 12.7% increase in revenue and a substantial rise in profit before tax by 264%. The company achieved notable advancements in product development, securing NMPA approvals for several new products across vascular surgery, cardiology, and nephrology. Acotec’s strategic focus on innovation and globalization is evident in its expanded hospital admissions and international market preparations, including collaborations with Boston Scientific Group plc. These efforts are expected to enhance Acotec’s market presence and diversify its revenue streams.
More about Acotec Scientific Holdings Limited
Acotec Scientific Holdings Limited operates in the medical technology industry, focusing on the development and commercialization of innovative medical devices. The company specializes in vascular and cardiology products, with a diverse portfolio that includes drug-coated balloons, aspiration systems, and ablation systems. Acotec is committed to advancing its market presence through product innovation and international expansion.
YTD Price Performance: 22.76%
Average Trading Volume: 117
Technical Sentiment Signal: Sell
Current Market Cap: €288.5M
For a thorough assessment of 6669 stock, go to TipRanks’ Stock Analysis page.